Accolate zafirlukast inflammation data

Researchers from the University of Aberdeen reported data from 2 open-label pragmatic trials showing that leukotriene antagonists Singular and Accolate produced equivalent increases in MiniAQLQ scores vs. inhaled corticosteroid controller medication (ICS) as first-line therapy or vs. long acting adrenergic receptor beta 2 agonists (LABAs) when added to ICS at 2 months. Equivalence was not proved at 2 years. Exacerbation rates and Asthma Control Questionnaire (ACQ) scores did not differ significantly between the 2 groups. Data were published in the New England Journal of Medicine. ...